Thomas L Andresen
Overview
Explore the profile of Thomas L Andresen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
160
Citations
2363
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bjorgvinsdottir U, Larsen J, Bak M, Andresen T, Munter R
J Control Release
. 2025 Jan;
379:982-992.
PMID: 39884438
Despite three decades of intense research, active targeting of liposomes have not been successfully achieved in a clinical setting. A potential explanation is that the clinically used liposomes lose their...
2.
Sporer E, Deville C, Straathof N, Bruun L, Koster U, Jensen M, et al.
EJNMMI Radiopharm Chem
. 2024 Dec;
9(1):92.
PMID: 39738813
Background: Brachytherapy (BT) is routinely used in the treatment of various cancers. Current BT relies on the placement of large sources of radioactivity at the tumor site, requiring applicators that...
3.
Schultz D, Kempen P, Primdahl S, Pereverzina M, Uhrenfeldt A, Alba E, et al.
ACS Appl Mater Interfaces
. 2024 Dec;
16(49):67192-67202.
PMID: 39621822
Recent investigations into autonomous ingestible microjet devices have demonstrated the feasibility of delivering many drug modalities directly into the gastrointestinal (GI) wall via the oral route. However, the expression and...
4.
Schultz D, Munter R, Cantin A, Kempen P, Jahnke N, Andresen T, et al.
Eur J Pharm Biopharm
. 2024 Nov;
205:114571.
PMID: 39490428
To quantify concentration and encapsulation efficiency (EE) of mRNA in lipid nanoparticles (LNPs) the RiboGreen assay is extensively used. As part of this assay, a surfactant is used to release...
5.
Henriksen N, Serrano-Chavez E, Fuglsang-Madsen A, Jensen L, Gottlieb H, Bue M, et al.
Antimicrob Agents Chemother
. 2024 Sep;
68(10):e0069124.
PMID: 39287404
The therapeutic challenges of orthopedic device-related infections and emerging antimicrobial resistance have attracted attention to drug delivery technologies. This study evaluates the preclinical efficacy of local single- and dual-antibiotic therapy...
6.
Wei P, Romano C, Li C, Clergeaud G, Andresen T, Henriksen J, et al.
Commun Biol
. 2024 Sep;
7(1):1158.
PMID: 39284859
Diseases caused by S. pneumoniae are the leading cause of child mortality. As antibiotic resistance of S. pneumoniae is rising, vaccination remains the most recommended solution. However, the existing pneumococcal...
7.
Jensen S, Jaehger D, Serrano-Chavez E, Halldorsdottir H, Engel T, Jorgensen J, et al.
Nat Commun
. 2024 Sep;
15(1):7687.
PMID: 39227589
Cancer curing immune responses against heterogeneous solid cancers require that a coordinated immune activation is initiated in the antigen avid but immunosuppressive tumor microenvironment (TME). The plastic TME, and the...
8.
Romano C, Jiang H, Tahvili S, Wei P, Keiding U, Clergeaud G, et al.
RSC Med Chem
. 2024 Aug;
15(8):2718-2728.
PMID: 39149099
iNKT cells - often referred as the "Swiss Army knife" of the immune system - have emerged as central players in cancer vaccine therapies. Glycolipids activating iNKT cells, such as...
9.
Munter R, Larsen J, Andresen T
J Colloid Interface Sci
. 2024 Jun;
674:139-144.
PMID: 38925059
Nucleic acid-based therapies are transforming medicine, but rely on an efficient delivery vehicle such as lipid nanoparticles (LNPs). Concerns exists in the nanomedicine field, that a large fraction of the...
10.
Niknezhad S, Mehrali M, Khorasgani F, Heidari R, Kadumudi F, Golafshan N, et al.
Bioact Mater
. 2024 Jun;
38:540-558.
PMID: 38872731
Bacteria can be programmed to deliver natural materials with defined biological and mechanical properties for controlling cell growth and differentiation. Here, we present an elastic, resilient and bioactive polysaccharide derived...